1-(BETA-D-Xylofuranosyl)-5-methylcytosine manufacturers
|
| | 1-(BETA-D-Xylofuranosyl)-5-methylcytosine Basic information |
| Product Name: | 1-(BETA-D-Xylofuranosyl)-5-methylcytosine | | Synonyms: | 1-(BETA-D-Xylofuranosyl)-5-methylcytosine;5-Methyl-xylo-cytidine;1-(b-D-Xylofuranosyl)-5-methylcytosine;2(1H)-Pyrimidinone, 4-amino-5-methyl-1-β-D-xylofuranosyl-;4-amino-1-((2R,3R,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidin-2(1H)-one | | CAS: | 18492-10-9 | | MF: | C10H15N3O5 | | MW: | 257.2432 | | EINECS: | | | Product Categories: | | | Mol File: | 18492-10-9.mol |  |
| | 1-(BETA-D-Xylofuranosyl)-5-methylcytosine Chemical Properties |
| Melting point | 205-207 °C(Solv: ethanol (64-17-5)) | | Boiling point | 537.5±60.0 °C(Predicted) | | density | 1.79±0.1 g/cm3(Predicted) | | pka | 13.48±0.70(Predicted) |
| | 1-(BETA-D-Xylofuranosyl)-5-methylcytosine Usage And Synthesis |
| Uses | 1-(β-D-Xylofuranosyl)-5-methylcytosine is a cytidine analog. Cytidine analogs have a mechanism of inhibiting DNA methyltransferases (such as Zebularine, HY-13420), and have potential anti-metabolic and anti-tumor activities[1]. | | References | [1] Robak T, Robak P. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des. 2012;18(23):3373-88. DOI:10.2174/138161212801227005
[2] Gowher H, et al. Mechanism of inhibition of DNA methyltransferases by cytidine analogs in cancer therapy. Cancer Biol Ther. 2004 Nov;3(11):1062-8. DOI:10.4161/cbt.3.11.1308 |
| | 1-(BETA-D-Xylofuranosyl)-5-methylcytosine Preparation Products And Raw materials |
|